Standout Papers

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <... 2021 2026 2022 2024174
  1. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial (2021)
    Scott D. Solomon, Rudolf A. de Boer et al. European Journal of Heart Failure

Citation Impact

41 standout
Sub-graph 1 of 18

Citing Papers

Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
2024 Standout
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
2024 Standout
2 intermediate papers

Works of Fredrik Öhrn being referenced

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
2021 Standout

Author Peers

Author SP MSOR Molecular Biology CCM EDM Last Decade Papers Cites
Fredrik Öhrn 39 8 32 136 131 7 269
Nathalie Job 1 16 401
James Beals 567 3 7 7 918
Femke van Kessel 16 4 4 5 183
Chun Qiu 23 2 20 401
Denis Theunynck 8 17 3 36 381

All Works

Loading papers...

Rankless by CCL
2026